(Q37801690)

23 August 2017

title

Chemotherapy against human African trypanosomiasis: is there a road to success? (English)

1 reference

23 August 2017

0 references

African trypanosomiasis

0 references

1 reference

Christian Burri

1

1 reference

23 August 2017

publication date

20 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

137

1 reference

23 August 2017

issue

14

1 reference

23 August 2017

page(s)

1987-1994

1 reference

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Human trypanosomiasis in the Ivory Coast: therapy and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Pentamidine dosage: a base/salt confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

inferred from DOI database lookup

7 January 2021

based on heuristic

The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

inferred from DOI database lookup

7 January 2021

based on heuristic

Eflornithine for the treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001137

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S0031182010001137

1 reference

23 August 2017

1 reference